Suppr超能文献

对于伴有黄疸的不可切除的胆管癌,采用胆汁引流、光动力疗法和化疗。

Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice.

机构信息

Federation of Digestive Diseases, Amiens North Hospital, Jules Verne University of Picardy, Amiens, France.

出版信息

J Gastroenterol Hepatol. 2009 Nov;24(11):1745-52. doi: 10.1111/j.1440-1746.2009.05915.x. Epub 2009 Sep 25.

Abstract

BACKGROUND AND AIM

The combination of photodynamic therapy and biliary stenting seems to be beneficial in the palliative treatment of unresectable cholangiocarcinoma. We aimed to assess the accuracy of photodynamic therapy in a single centre.

METHODS

Fourteen selected patients, with jaundice related to unresectable cholangiocarcinoma, underwent photodynamic therapy and biliary stenting (with or without chemotherapy). Photofrin was injected intravenously (2 mg/kg) 2 days before intraluminal photoactivation. In case of malignant progression, photodynamic therapy was repeated. The outcome parameters were overall survival and quality of life.

RESULTS

There were eight men and six women (median age: 67 [42-81]). Unresectability was related to a low Karnofski index (n = 2), peritoneal carcinomatosis (n = 4), vascular involvement (n = 3), invasion of the hepatoduodenal ligament (n = 2) and an under-sized liver remnant (n = 3). Biliary stenting was efficient (> or = 50% total bilirubin) in 78.5% of cases. Eight patients developed cholangitis. The mean number of photodynamic therapy procedures was two (1-4). Six (43%) patients needed > or = 2 procedures. No severe toxicity was noted. Photodynamic therapy improved the Karnofski index in 64% of cases. Six (42.8%) patients received concomitant chemotherapy (gemcitabine). The median survival time was 13.8 [0.7-29.2] months. The 3-, 6- and 12-month survival rates were 85%, 77% and 77%, respectively.

CONCLUSION

These results confirm the beneficial effect of biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma in selected patients with jaundice.

摘要

背景与目的

光动力疗法联合胆道支架置入术似乎对不可切除的胆管癌的姑息治疗有益。我们旨在评估单一中心光动力疗法的准确性。

方法

14 名因不可切除的胆管癌引起黄疸的患者接受了光动力疗法和胆道支架置入术(联合或不联合化疗)。在腔内光激活前 2 天,静脉注射血卟啉单甲醚(2mg/kg)。如果恶性进展,重复光动力疗法。观察的结局参数是总生存期和生活质量。

结果

患者包括 8 名男性和 6 名女性(中位年龄:67[42-81]岁)。不可切除性与低卡氏评分(n=2)、腹膜转移(n=4)、血管受累(n=3)、肝十二指肠韧带侵犯(n=2)和肝剩余体积小(n=3)有关。胆道支架置入术在 78.5%的病例中有效(总胆红素降低≥50%)。8 例患者发生胆管炎。光动力疗法的平均次数为 2 次(1-4 次)。6(43%)例患者需要≥2次治疗。未观察到严重毒性。光动力疗法使 64%的患者卡氏评分提高。6(42.8%)例患者接受了联合化疗(吉西他滨)。中位生存时间为 13.8[0.7-29.2]个月。3、6 和 12 个月的生存率分别为 85%、77%和 77%。

结论

这些结果证实了在选定的黄疸不可切除胆管癌患者中,胆道引流、光动力疗法和化疗联合治疗是有益的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验